Consistent with these results, our finding showed that HLA-G2/6, but not HLA-G1/4/5 status, is significantly associated with the survival of patients with colon cancer (p = 0.045), but not in those with rectal cancer, revealing that distinct HLA-G isoforms could have unique clinical relevance. Here, HLA-G is linked to rectal cancer.